The American pharmaceutical company, Teligent, has opened its first unit in Europe – a development lab in Tallinn, the capital of Estonia.
The company, which develops, manufactures and markets pharmaceutical products for use by doctors and patients in the United States and Canada, has never ventured out of the North American market. A relatively small producer, its 150 employees are based in New Jersey, Toronto, Montreal – and now in Tallinn.
The Estonian lab employs 12 people and specialises in analytical chemistry, supporting the main lab in the US. The Tallinn branch will also be responsible for supporting the firm’s supply chain and quality operations. Teligent invested €1 million to set up the Estonian lab, but is planning for more.
According to Enterprise Estonia, the state-run agency to promote foreign investment, Teligent considered other destinations for its European operation – including Switzerland and Ireland – but finally chose Estonia. The decision was based on the tax rate, legal system and the ease of administering a company. The Estonian e-residency programme also played a role, by making long-distance administration easier.
Cover: A chemistry lab (the image is illustrative/courtesy of shushi168.com). Source: The Estonian Investment Agency.